The costs of medical care are always increasing. To limit them, several pharmaceutical laboratories have developed substitutes of effective, but costly, products. They have produced biosimilars of G-CSF-like filgrastim-Neupogen from Amgen pharmaceutical (Thousand Oaks, CA, USA). The methods of synthesis are quite different from the synthesis of the original product because they utilise bacterial support to yield new bioproducts with lower costs, but that induces modifications of the molecules like glycosylation and phosphorylation. 1, 2 But, final products already seem to be as effective as the classical version of G-CSF. Despite the limited number of prospective studies in the field of haematology, these biosimilars were awarded the same authorisations of use as those of the original product. There are few data available on the use of biosimilars of filgrastim in PBSCT. 3, 4 Because of the potentially decreased costs, biosimilars of G-CSF have become available in our hospital. Over the course of a year, we have used these products for patients with lymphoma and myeloma who underwent PBSCT. We initiated a retrospective study comparing the efficacy on BM recovery with the use of biosimilars of G-CSF vs a historical cohort of patients. 5 We identified 88 consecutive patients who underwent PBSCT in our centre: 50 patients were treated with classical G-CSF (25 with lymphoma and 25 with myeloma) and 38 patients (25 with lymphoma and 13 with myeloma) received biosimilars of G-CSF. Patient characteristics are summarised in Table 1 . Patients with lymphoma received a BEAM conditioning regimen, and myeloma patients were treated with a melphalan (140 or 200 mg/m 2 ) conditioning regimen. The injection of G-CSF began at day 5 after PBSCT injection. We evaluated eight clinical parameters: the number of G-CSF injections, the number of days of hospitalisation, the number of units of red blood cell or platelet transfusions, the days on which body temperature exceeded 38 1C, the days of parenteral nutrition, the weight loss and the hospitalisation costs. We also studied four biological parameters: the number of CD34 þ cells injected, the days on which leucocyte counts were less than 1 Â 10 9 cells/L, the days on which Hb was less than 90 g/L or platelet counts were less than 50 Â 10 9 /L. No differencies appeared in the global characteristics of the two groups of patients (Table 1) . Furthermore, the numbers of CD34 þ cells injected were identical in each subgroup. Despite the apparent superiority of classical G-CSF stimulation, we did not observe statistically significant differences for the 12 parameters studied between the two groups of patients with lymphoma and myeloma. Only one patient from the biosimilar group died from transplantationrelated mortality. These data are summarised in Table 2 .
Since the 1990s, several groups have studied the role of G-SCF as a supportive therapy following PBSCT in cases of lymphoma, myeloma or solid tumours. The use of G-CSF reduced the time to neutrophil recovery and the number of days with fever. 6, 7 For this reason, the American Society of Hematology, the British Society of Haematology and the European Society of Haematology-European Group of Bone Marrow Transplantation recommend the use of G-CSF after PBSCT. [8] [9] [10] Recently, some pharmaceutical laboratories have lost the patent for their commercially profitable products (IFN a2a, Epoetin a and b, and filgrastim). Many pharmaceutical companies have developed biosimilars of G-CSF with the aim of reducing costs. 3 Biosimilars of filgrastim are produced differently than classical filgrastim by the use of different bacterial supports. The drugs are then produced in greater quantity with lower costs. However, the variation in production induced some changes in the molecular composition of G-CSF biosimilars, specifically in O-and N-glycosylation, phosphorylation, lipid attachment or cleavage.
1 Consequently, the biosimilars produced are unique molecules and are not generic versions of the innovator biopharmaceuticals. Inherent differences between biosimilars and the original products may produce dissimilarities in clinical efficacy, safety and immunogenicity. Biosimilars could be used in the same therapeutic indications as classical G-CSF. Previously published papers in oncology or haematology suggest the benefits of using those drugs. [1] [2] [3] To date, few data exist concerning biosimilars of G-CSF and PBSCT. 4 In our hospital, biosimilars of G-CSF are available for hospitalised patients who undergo PBSCT. We performed a prospective study comparing BM recovery of the patients who received biosimilars with those who received classical G-CSF. The initial characteristics of the patients and the numbers of CD34 þ cells injected were identical. In all, 12 clinical and biological parameters were studied under the given conditions. No significant differences could be detected for the two types of G-CSF used as stimulation for patients in the lymphoma and myeloma subgroups after PBSCT. The use of biosimilars of G-CSF after PBSCT does not seem to modify the biological parameters of BM recovery. This seems to be true for the population with lymphoma for which the number of patients in the two subgroups was the same. The trend was the same in the myeloma subgroups despite the difference in the number of patients due to modification of the patients' recruitment. Furthermore, we studied the costs of G-CSF, and we observed significant differences (Po0.00001) between the two subgroups, confirming that biosimilars are cheaper than classical filgrastim (127 vs 617 euros/patient in the lymphoma subgroup and 140 vs 564 euros/patient in the myeloma subgroup). It is interesting to note that the global costs of hospitalisation (Table 2) are not really affected by the use of biosimilars because the costs of these drugs are less than 1% of the global costs of the PBSCT procedure (127 vs 42 838 euros in the lymphoma group and 140 vs 32 894 euros in the myeloma group). This study shows that biosimilars of G-CSF are equivalent to classical products in terms of efficacy when used for stimulation after PBSCT in lymphoma and myeloma patients. It is also important to note that these products had a minimal effect on the global costs of the procedure. Even if the number of patients in our study is sufficient to observe these tendencies, a randomised study should be conducted to confirm these results. Letter to the Editor
